Rapport Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Rapport Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Rapport Therapeutics, Inc. RAPP.OQ reported a quarterly adjusted loss of $1.19 per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -75 cents. The mean expectation of thirteen analysts for the quarter was for a loss of 95 cents per share. Wall Street expected results to range from $-1.04 to -84 cents per share.
Reported revenue was zero; analysts expected zero.
Rapport Therapeutics, Inc.'s reported EPS for the quarter was a loss of $1.19.
The company reported a quarterly loss of $56.62 million.
Rapport Therapeutics, Inc. shares had risen by 1.3% this quarter and gained 39.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 15% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
This summary was machine generated from LSEG data August 5 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.95 | -1.19 | Missed |
Mar. 31 2026 | -0.67 | -0.42 | Beat |
Dec. 31 2025 | -0.68 | -0.72 | Missed |
Sep. 30 2025 | -0.78 | -0.71 | Beat |